[Veno-occlusive syndrome with acute liver dystrophy following decarbazine therapy of malignant melanoma (author's transl)]
- PMID: 7218735
- DOI: 10.1007/BF01476580
[Veno-occlusive syndrome with acute liver dystrophy following decarbazine therapy of malignant melanoma (author's transl)]
Abstract
Case report about death due to veno-occlusive liver disease following Dacarbazine treatment: 9 years after surgical treatment of malignant melanoma of the trunk a 68-years old patient developed lymph node metastases in the right axilla, which were removed immediately by surgical excision. One month before the patient had undergone surgical treatment of empyema of the gallbladder: Cholecystectomy and appendectomy were performed, postoperative recovery was uncomplicated. On account of the second lymph node metastasis within nine months adjuvant treatment with Dacarbazine was agreed and started one month later. After having performed the first course of treatment without any hints to intolerance the patient suddenly exhibited severe shock symptoms on the fourth day of the second course. Clinically residual myocardial infarct or pulmonary embolism were assumed, but could not be verified. The patient delivered increasing hepatomegaly. A massive increase in transaminase values was noted. Hemostasiologic changes with decreased Quick value occurred. The patient died of cerebral hemorrhage five days after beginning the second Dacarbazine cycle. Autopsy findings were severe liver cell necroses as well as liver vein thromboses, no metastases of melanoma could be found. Hepatotoxicity of Dacarbazine and the mechanism of liver vein thrombosis are discussed with special regards to possible hemostasiologic changes and sensibilisation due to Dacarbazine and/or previous liver cell damage.
Similar articles
-
[Dacarbazine in malignant melanoma. Rare, severe side-effect: Budd-Chiari-syndrome (author's transl)].Z Hautkr. 1982 Jul 1;57(13):971-80. Z Hautkr. 1982. PMID: 7113323 German.
-
[Budd-Chiari syndrome during treatment with dacarbazine (DTIC) (author's transl)].Dtsch Med Wochenschr. 1980 Feb 15;105(7):230-3. doi: 10.1055/s-2008-1070640. Dtsch Med Wochenschr. 1980. PMID: 6986251 German.
-
Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.J Surg Oncol. 1984 Dec;27(4):268-70. doi: 10.1002/jso.2930270415. J Surg Oncol. 1984. PMID: 6503301
-
Drug-induced vascular and sinusoidal lesions of the liver.Baillieres Clin Gastroenterol. 1988 Apr;2(2):481-500. doi: 10.1016/0950-3528(88)90013-9. Baillieres Clin Gastroenterol. 1988. PMID: 3044472 Review.
-
Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients.Melanoma Res. 2013 Oct;23(5):381-9. doi: 10.1097/CMR.0b013e3283649a97. Melanoma Res. 2013. PMID: 23880781 Review.
Cited by
-
Mechanisms of hepatotoxicity caused by dacarbazine in rats.J Cancer Res Clin Oncol. 1993;119(8):475-81. doi: 10.1007/BF01215928. J Cancer Res Clin Oncol. 1993. PMID: 8509437 Free PMC article.
-
Drug-induced liver injury: is it somehow foreseeable?World J Gastroenterol. 2009 Jun 21;15(23):2817-33. doi: 10.3748/wjg.15.2817. World J Gastroenterol. 2009. PMID: 19533803 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical